Jazz Pharmaceuticals to buy Chimerix for $935 million
MLex Summary: Jazz Pharmaceuticals has agreed to buy biotech firm Chimerix for $935 million in cash. The transaction has been approved by both companies and is expected to close in the...To view the full article, register now.
Already a subscriber? Click here to view full article